ZAI Lab Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ZAI Lab Limited - overview
Established
2014
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2014 and based in Shanghai, China, ZAI Lab Limited operates as a biopharmaceutical company that discovers and develops therapeutics to address oncology, autoimmune and infectious diseases, with an R&D center in Shanghai, clinical and regulatory offices in Beijing, manufacturing and R&D facilities in Suzhou, commercial offices in Hong Kong, Taiwan, Guangzhou, and U. S. As of March 31, 2022, ZAI Lab has more than 1,999 employees. In September 2020, it was listed on the Hong Kong Stock Exchange with stock code 9688.
In September 2017, it completed USD 172 million NASDAQ IPO. The founder and CEO, Samantha Du, used to serve on the boards at Sequoia Capital China and led four healthcare investments. The company focused on bringing medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders. The products include ZEJULA (niraparib), Tumor Treating Fields (TTFields) therapy, QINLOCK (ripretinib), and NUZYRA (omadacycline).
The clinical development team currently manages more than 50 ongoing or planned clinical trials. The company will use the funds to complete clinical trials and advance new drug candidates, support new business development and licensing opportunities, and expand commercialization operations. In December 2024, ZAI Lab Limited raised CNY 300 million in venture debt funding from new investor Bank of Communications.
Current Investors
OrbiMed Advisors, Vivo Capital, Qiming Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.zailaboratory.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.